Patent Yard Sign in
Expired European patentEurope

Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

EP 0876397 B1 · Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH

EPO PDF

Overview

The published document from the EPO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its EPO record in Patent Yard's archive of European patents past their term. Its claims, description and drawings are in the EPO PDF and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed February 5, 1997 and granted May 2, 2003. A European patent lasts at most 20 years from filing, so its term ended February 5, 2017.
  • A supplementary protection certificate, which can extend a medicine or crop-protection patent, adds at most five and a half years, so even that would have ended by August 5, 2022.
  • We check European rights only. A US or other national patent in its family could still be in force: check its family on Espacenet or Google Patents.
FiledFebruary 5, 1997
PublishedNovember 11, 1998
GrantedMay 2, 2003
Term endedFebruary 5, 2017
Application numberEP 97906894
Classification (CPC)A61K40/11 +2 more

Timeline

Timeline From EPO dates

1998200020022004200620082010201220142016Application filedFeb 5, 1997PublishedNov 11, 1998Patent grantedMay 2, 2003Term endedFeb 5, 2017

Sources & verification